PMID- 30865013
OWN - NLM
STAT- MEDLINE
DCOM- 20200227
LR  - 20200227
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Linking)
VI  - 114
IP  - 6
DP  - 2019 Jun
TI  - Physical Activity, Fatty Liver, and Glucose Metabolism Over the Life Course: The 
      Lifelines Cohort.
PG  - 907-915
LID - 10.14309/ajg.0000000000000168 [doi]
AB  - OBJECTIVES: We examined the dose-dependent association of habitual 
      moderate-to-vigorous physical activity (MVPA) with the biochemical markers for 
      nonalcoholic fatty liver disease (NAFLD) and whether this association changes 
      with age and degree of impaired glucose metabolism. We also investigated whether 
      the associations depend on the domain of MVPA. METHODS: In this study, using data 
      from the population-based Lifelines cohort (N = 42,661), MVPA was self-reported 
      on the short questionnaire to assess health-enhancing physical activity. NAFLD 
      was defined as a fatty liver index value of >60, based on body mass index, waist 
      circumference, plasma triglycerides, and gamma-glutamyltransferase. Glucose 
      metabolism was defined as normal (NGM), impaired (IGM), and type 2 diabetes 
      mellitus (T2DM). Exclusion criteria were previously diagnosed hepatitis or 
      cirrhosis and excessive alcohol use. All analyses were adjusted for age, sex, and 
      education. RESULTS: Higher MVPA was dose dependently associated with a lower risk 
      of having NAFLD: compared with "No MVPA," the odds ratios (ORs) (95% confidence 
      intervals) for MVPA quintiles were 0.78 (0.71-0.86), 0.64 (0.58-0.70), 0.53 
      (0.48-0.59), 0.51 (0.46-0.56), and 0.45 (0.41-0.50) for the highest level of 
      MVPA. The association between MVPA and NAFLD was stronger for more impaired 
      glucose status (ORNGM = 0.49 (0.42-0.57), ORIGM = 0.46 (0.40-0.54), ORT2DM = 0.42 
      (0.27-0.66)) and for older age (OR20-40 years = 0.51 (0.42-0.62), OR60-80 years = 
      0.37 (0.29-0.48)) with the highest level of MVPA, relative to No MVPA. No 
      favorable association was observed for occupational MVPA. With regard to MVPA and 
      fibrosis, associations with fibrosis markers showed contradictory results. 
      CONCLUSIONS: Higher MVPA levels are dose dependently associated with a lower 
      NAFLD risk. This association is stronger in people with diabetes and older 
      adults.
FAU - Byambasukh, Oyuntugs
AU  - Byambasukh O
AD  - Unit of Lifestyle Medicine in Obesity and Diabetes, Department of Epidemiology, 
      University Medical Center Groningen, University of Groningen, Groningen, the 
      Netherlands.
AD  - Department of Internal Medicine, Mongolian National University of Medical 
      Sciences, Ulaanbaatar, Mongolia.
FAU - Zelle, Dorien
AU  - Zelle D
AD  - Department of Internal Medicine, University Medical Center Groningen, University 
      of Groningen, Groningen, the Netherlands.
FAU - Corpeleijn, Eva
AU  - Corpeleijn E
AD  - Unit of Lifestyle Medicine in Obesity and Diabetes, Department of Epidemiology, 
      University Medical Center Groningen, University of Groningen, Groningen, the 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/*physiology
MH  - Biomarkers/blood
MH  - Blood Glucose/*metabolism
MH  - Body Mass Index
MH  - Chromatography, High Pressure Liquid
MH  - Disease Progression
MH  - Exercise/*physiology
MH  - Female
MH  - Follow-Up Studies
MH  - *Forecasting
MH  - Humans
MH  - Liver Function Tests
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/blood/epidemiology/*physiopathology
MH  - Prevalence
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Risk Factors
MH  - Young Adult
EDAT- 2019/03/14 06:00
MHDA- 2020/02/28 06:00
CRDT- 2019/03/14 06:00
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2020/02/28 06:00 [medline]
PHST- 2019/03/14 06:00 [entrez]
AID - 10.14309/ajg.0000000000000168 [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2019 Jun;114(6):907-915. doi: 10.14309/ajg.0000000000000168.